Professor Zhang Jie from the National Center for Geriatrics, Beijing Hospital, states that insulin degludec/insulin aspart has demonstrated consistent and significant HbA1c reduction and low hypoglycemia risk worldwide. The core behind this therapeutic consistency lies in its unique pharmacological design.Insulin degludec/insulin aspart is a soluble dual-component insulin formulation, composed of 70% ultra-long-acting insulin degludec and […]
Tag: Insulin Degludec/Insulin Aspart
Post-Marketing Multinational Real-World Studies of Insulin Degludec/Insulin Aspart: Confirming Its Efficacy and Safety
In the era of evidence-based medicine, randomized controlled trials (RCTs) provide robust evidence for new drug approval, while real-world evidence (RWE) helps reveal the actual performance of drugs in complex and diverse clinical settings. Since its global launch, insulin degludec/insulin aspart has not only demonstrated favorable efficacy and safety in registration trials but also continues […]